These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 32535897)

  • 21. The Solubility-Permeability Trade-Off of Progesterone With Cyclodextrins Under Physiological Conditions: Experimental Observations and Computer Simulations.
    Sun L; Zhang B; Sun J
    J Pharm Sci; 2018 Jan; 107(1):488-494. PubMed ID: 29031956
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of inclusion complexation on the transepithelial transport of a lipophilic substance in vitro.
    Cho MJ; Chen FJ; Huczek DL
    Pharm Res; 1995 Apr; 12(4):560-4. PubMed ID: 7596992
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Fluconazole and Itraconazole on the Pharmacokinetics of Erdafitinib in Healthy Adults: A Randomized, Open-Label, Drug-Drug Interaction Study.
    Poggesi I; Li LY; Jiao J; Hellemans P; Rasschaert F; de Zwart L; Snoeys J; De Meulder M; Mamidi RNVS; Ouellet D
    Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):101-111. PubMed ID: 31673875
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improvement of ursodeoxycholic acid bioavailability by 2-hydroxypropyl-beta-cyclodextrin complexation in healthy volunteers.
    Panini R; Vandelli MA; Forni F; Pradelli JM; Salvioli G
    Pharmacol Res; 1995; 31(3-4):205-9. PubMed ID: 7630860
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimization of β-cyclodextrin consolidated micellar dispersion for promoting the transcorneal permeation of a practically insoluble drug.
    Sayed S; Elsayed I; Ismail MM
    Int J Pharm; 2018 Oct; 549(1-2):249-260. PubMed ID: 30077759
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyclodextrin Reduces Intravenous Toxicity of a Model Compound.
    Mantik P; Xie M; Wong H; La H; Steigerwalt RW; Devanaboyina U; Ganem G; Shih D; Flygare JA; Fairbrother WJ; Chakravarty P; Russell D; Fernandez GE; Narang AS
    J Pharm Sci; 2019 Jun; 108(6):1934-1943. PubMed ID: 30639736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative interaction of 2-hydroxypropyl-beta-cyclodextrin and sulfobutylether-beta-cyclodextrin with itraconazole: phase-solubility behavior and stabilization of supersaturated drug solutions.
    Brewster ME; Vandecruys R; Peeters J; Neeskens P; Verreck G; Loftsson T
    Eur J Pharm Sci; 2008 Jul; 34(2-3):94-103. PubMed ID: 18420390
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human.
    Salphati L; Pang J; Plise EG; Lee LB; Olivero AG; Prior WW; Sampath D; Wong S; Zhang X
    Drug Metab Dispos; 2012 Sep; 40(9):1785-96. PubMed ID: 22696419
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The physicochemical characteristics and bioavailability of indomethacin from beta-cyclodextrin, hydroxyethyl-beta-cyclodextrin, and hydroxypropyl-beta-cyclodextrin complexes.
    Jambhekar S; Casella R; Maher T
    Int J Pharm; 2004 Feb; 270(1-2):149-66. PubMed ID: 14726131
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic study of a new synthetic MMP inhibitor (Ro 28-2653) after IV and oral administration of cyclodextrin solutions.
    Piette M; Evrard B; Frankenne F; Chiap P; Bertholet P; Castagne D; Foidart JM; Delattre L; Piel G
    Eur J Pharm Sci; 2006 Jun; 28(3):189-95. PubMed ID: 16520026
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral bioavailability and hypoglycaemic activity of tolbutamide/cyclodextrin inclusion complexes.
    Veiga F; Fernandes C; Teixeira F
    Int J Pharm; 2000 Jul; 202(1-2):165-71. PubMed ID: 10915940
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The pharmacokinetics of beta-cyclodextrin and hydroxypropyl-beta-cyclodextrin in the rat.
    Frijlink HW; Visser J; Hefting NR; Oosting R; Meijer DK; Lerk CF
    Pharm Res; 1990 Dec; 7(12):1248-52. PubMed ID: 2095562
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improvement of dissolution and bioavailability of nitrendipine by inclusion in hydroxypropyl-beta-cyclodextrin.
    Choi HG; Kim DD; Jun HW; Yoo BK; Yong CS
    Drug Dev Ind Pharm; 2003 Nov; 29(10):1085-94. PubMed ID: 14677769
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of aging on crystallization, dissolution and absorption characteristics of amorphous tolbutamide-2-hydroxypropyl-beta-cyclodextrin complex.
    Kimura K; Hirayama F; Arima H; Uekama K
    Chem Pharm Bull (Tokyo); 2000 May; 48(5):646-50. PubMed ID: 10823700
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam.
    Reese MJ; Bowers GD; Humphreys JE; Gould EP; Ford SL; Webster LO; Polli JW
    Xenobiotica; 2016; 46(5):445-56. PubMed ID: 26340566
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and disposition of anlotinib, an oral tyrosine kinase inhibitor, in experimental animal species.
    Zhong CC; Chen F; Yang JL; Jia WW; Li L; Cheng C; Du FF; Zhang SP; Xie CY; Zhang NT; Olaleye OE; Wang FQ; Xu F; Lou LG; Chen DY; Niu W; Li C
    Acta Pharmacol Sin; 2018 Jun; 39(6):1048-1063. PubMed ID: 29620050
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of the interaction of 2-hydroxypropyl-beta-cyclodextrin with itraconazole at pH 2, 4, and 7.
    Peeters J; Neeskens P; Tollenaere JP; Van Remoortere P; Brewster ME
    J Pharm Sci; 2002 Jun; 91(6):1414-22. PubMed ID: 12115841
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Investigation of the improved effects of 2-hydroxypropyl-beta-cyclodextrin on solubility, dissolution rate, and intestinal absorptive profile of tanshinone IIA in rats.
    Wang L; Jiang X; Li C; Ren J
    Arch Pharm Res; 2007 Aug; 30(8):1020-6. PubMed ID: 17879757
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro and in vivo studies on the complexes of vinpocetine with hydroxypropyl-beta-cyclodextrin.
    Nie S; Fan X; Peng Y; Yang X; Wang C; Pan W
    Arch Pharm Res; 2007 Aug; 30(8):991-1001. PubMed ID: 17879753
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-beta-cyclodextrin oral solution or coated-pellet capsules.
    Glasmacher A; Hahn C; Molitor E; Marklein G; Sauerbruch T; Schmidt-Wolf IG
    Mycoses; 1999; 42(11-12):591-600. PubMed ID: 10680434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.